Canabidiol Prati-Donaduzzi is the first and unique Brazilian cannabis-based product approved by the National Health Regulatory Agency (ANVISA).
It is a phytopharmaceutical (a complex mixture derived from plant sources that is used as a medicine or drug) and physicians determine its therapeutic indication in the prescription. Its sale is subject to the presentation of a type B (blue) prescription, which is of controlled numbering.
Canabidiol Prati-Donaduzzi is a 200 mg/ml oral solution product. In its 30 mL presentation, there is the corresponding 6,000 mg of Cannabidiol. The product has a high concentration of the active substance, which can enable the administration of lower doses.
Canabidiol Prati-Donaduzzi is produced from the pure active ingredient, in other words, containing only Cannabidiol, without any other substance from Cannabis, since the vast majority of them do not have scientific studies that prove their activity and safety. The product is free of THC (tetrahydrocannabinol) - psychoactive compound.
The product formulation is carried out by the pharmaceutical industry, in its industrial park, located in Toledo in the Western Paraná, as well as the sales and distribution logistics, which was expanded by the partnership with Profarma and Santa Cruz distributors. This means that pharmacies throughout Brazil are served.
The use of a highly purified raw material and the performance of all required quality tests enables the safety and quality assurance of Canabidiol Prati-Donaduzzi lot by lot. Canabidiol Prati-Donaduzzi carries a lot of responsibility and the social commitment of a Brazilian industry.
The product is a version of the drug that is in the final stage of multicenter clinical studies, under the coordination of Hospital das Clínicas of São Paulo University (Ribeirão Preto Campus). For more than six years, Prati-Donaduzzi has been investing in disruptive and highly innovative research in the field of cannabinoids.